Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma

Study Overview
=================
Brief Summary
-----------------
This clinical trial studies genetic biomarkers from saliva samples in patients with Ewing sarcoma. Studying samples of saliva from patients with cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.

Detailed Description
-----------------
PRIMARY OBJECTIVES: I. To determine the association between the length of Ewing sarcoma breakpoint region 1-Friend leukemia virus integration 1 (EWS-FLI1) fusion protein binding sites (microsatellites) and risk of Ewing's sarcoma (ES). II. To determine the frequency and commonality of Caucasian ancestral markers in cases of ES self-identified as non-Caucasian (African-American, Asian, Hispanic). III. To determine the association between genomic variants in ES-related genes and hernia development (i.e. the integrin signaling pathway) and risk of ES. OUTLINE: Genomic DNA is extracted from participants' saliva samples and analyzed for expression of EWS-FLI1 and other ES-target genes.

Official Title
-----------------
Genetic Epidemiology of Ewing's Sarcoma

Conditions
-----------------
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET)

Intervention / Treatment
-----------------
* Other: laboratory biomarker analysis
* Other: questionnaire administration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patient is enrolled on ACCRN07 The patient has a diagnosis of Ewing Sarcoma (International Classification of Diseases [ICD] code morphology 9260; topography C40.0-C41.9, C76.0-C76.8, C80.9) and is registered with Children's Oncology Group (COG) by a North American member institution The patient must be diagnosed with Ewing sarcoma between December 24, 2007 and December 31, 2015 The patient must have at least one biological parent alive and willing to participate All questionnaire respondents must understand English or Spanish Concomitant treatment on a therapeutic trial is not required
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ancillary-Correlative (genetic epidemiology of Ewing sarcoma)<br>Genomic DNA is extracted from participants' saliva samples and analyzed for expression of EWS-FLI1 and other ES-target genes. | Other: laboratory biomarker analysis<br>* Correlative studies<br>Other: questionnaire administration<br>* Ancillary studies<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Main effect of gene polymorphisms | Risk ratios (RR) for the main effect of gene polymorphisms will be calculated using log-linear models. RRs and 95% confidence intervals for the gene-environment interaction are calculated by stratifying the likelihood according to case exposure. | Up to 5 years |